Effect of alendronate on resorption of transplanted bone in mice

被引：0

作者：

Kawata, T ^{[1
]}

Tenjou, K ^{[1
]}

Tokimasa, C ^{[1
]}

Fujita, T ^{[1
]}

Kaku, M ^{[1
]}

Matsuki, A ^{[1
]}

Kohno, S ^{[1
]}

Tsutsui, K ^{[1
]}

Ohtani, J ^{[1
]}

Motokawa, M ^{[1
]}

Kobayakawa, T ^{[1
]}

Shigekawa, M ^{[1
]}

Tohma, Y ^{[1
]}

Tanne, K ^{[1
]}

机构：

[1] Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthodont & Craniofacial Dev Biol, Minami Ku, Hiroshima 7348553, Japan

来源：

BIOMEDICAL RESEARCH-TOKYO | 2003年 / 24卷 / 03期

关键词：

MEVALONATE PATHWAY; BISPHOSPHONATES; DIPHOSPHONATE; HYPERCALCEMIA; OSTEOCLAST; INHIBITION; APOPTOSIS; PROTEIN; RATS;

D O I：

10.2220/biomedres.24.147

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Alendronate, one of the bisphosphonates, is known to have an inhibitory effect on bone resorption. The purpose of study was to investigate the effects of alendronate on ectopic bone graft resorption and to determine the optimal dose in the mouse. In control group, segments of chopped tarsal bone were immersed in saline solution and auto-grafted. In experimental groups, the same bone segments were immersed in alendronate ranging in concentration from 10(-4) to 10(-6)M prior to transplantation. The grafted bone in the control group disappeared due to resorption by osteoclasts within 5 weeks. In the experimental groups, the area of bone tissue decreased by only 20-40% at 5 weeks post-operatively. The transplanted bone volume in alendronate-treated groups exhibited a tendency of dose-dependent increase, being highest in the 10(-4)M group. The number of osteoclasts was significantly less in the alendronate-treated groups than in the controls. These results suggested that the alendronate inhibits resorption of ectopic bone graft at a concentration of 10(-4) to 10(-6) M.

引用

页码：147 / 151

页数：5

共 11 条

[1] Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates:: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
Benford, HL
Frith, JC
Auriola, S
Mönkkönen, J
Rogers, MJ
[J]. MOLECULAR PHARMACOLOGY, 1999, 56 (01) : 131 - 140
[2] EFFECTS OF AMINO-BUTYLIDENE DIPHOSPHONATE IN HYPERCALCEMIA DUE TO MALIGNANCY
BICKERSTAFF, DR
ODOHERTY, DP
MCCLOSKEY, EV
HAMDY, NAT
MIAN, M
KANIS, JA
[J]. BONE, 1991, 12 (01) : 17 - 20
[3] INTESTINAL CALCIUM ABSORPTION, CA-BINDING PROTEIN, AND CA-ATPASE IN DIPHOSPHONATE-TREATED RATS
BONJOUR, JP
RUSSELL, RGG
MORGAN, DB
FLEISCH, HA
[J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1973, 224 (05): : 1011 - 1017
[4] Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
Coxon, FP
Helfrich, MH
Van't Hof, R
Sebti, S
Ralston, SH
Hamilton, A
Rogers, MJ
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (08) : 1467 - 1476
[5] BISPHOSPHONATES - PHARMACOLOGY AND USE IN THE TREATMENT OF TUMOR-INDUCED HYPERCALCEMIC AND METASTATIC BONE-DISEASE
FLEISCH, H
[J]. DRUGS, 1991, 42 (06) : 919 - 944
[6] GLOWACKI J, 1981, LANCET, V1, P959
[7] HUGHES DE, 1995, J BONE MINER RES, V10, P1478
[8] Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
Luckman, SP
Hughes, DE
Coxon, FP
Russell, RGG
Rogers, MJ
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (04) : 581 - 589
[9] Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mst1 kinase during apoptosis - A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
Reszka, AA
Halasy-Nagy, JM
Masarachia, PJ
Rodan, GA
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (49) : 34967 - 34973
[10] RIZZOLI R, 1989, J BONE MINER RES, V4, P759

← 1 2 →